
Cigna (CI) Stock Forecast & Price Target
Cigna (CI) Analyst Ratings
Bulls say
Cigna Group is positioned for continued robust growth, particularly within its Evernorth segment, which is expected to enhance patient satisfaction while driving lower costs and improved health outcomes. The company anticipates significant margin recovery by 2027, with a projected 100 basis points recapture for its healthcare portfolio, contributing to long-term growth expectations of 7%-10% in the Healthcare segment. Furthermore, strong free cash flow is expected to support ongoing capital deployment, broadening service offerings and sustaining core growth trends, thereby presenting a favorable valuation outlook for the stock.
Bears say
Cigna Group faces significant financial challenges as it anticipates a decline in Evernorth Adjusted Operating Income (AOI) for 2026, primarily due to pressures from pharmacy benefit management (PBM) margins and the impact of transitioning to a rebate-free model, which is expected to reduce earnings by $500 million to $600 million. Moreover, the expected decline in AOI margins among its top three customers and the overall shift to lower-priced contracts present further margin erosion risks. Additionally, Cigna's outlook is clouded by potential client losses, competitive pressures within the specialty drug market, and uncertainties regarding healthcare cost management in the U.S. market.
This aggregate rating is based on analysts' research of Cigna and is not a guaranteed prediction by Public.com or investment advice.
Cigna (CI) Analyst Forecast & Price Prediction
Start investing in Cigna (CI)
Order type
Buy in
Order amount
Est. shares
0 shares